The Competition Board has decided to open an investigation into 11 undertakings operating in the nuclear medicine market.
In a statement, the Board announced that the investigation aims to determine whether the undertakings violated Article 4 of the Law on the Protection of Competition by engaging in collusion and/or concerted practices.
Companies under investigation
The statement also listed the 11 undertakings subject to the investigation:
- Medicheck Nükleer Ürünler Sanayi ve Ticaret AŞ
- Referans Nükleer Tıp Sağlık Ltd. Şti.
- Fefa Nükleer Tıp Ticaret Ltd. Şti.
- Sintias Moleküler Sağlık Ürünleri Sanayi ve Ticaret AŞ
- Sintias Nükleer Tıp Ticaret Ltd. Şti.
- Nukleon Nükleer Teknoloji Araştırma Sanayi ve Ticaret Ltd. Şti.
- Bianco Sağlık Ürünleri Ticaret Pazarlama Ltd. Şti.
- Nukleus Sağlık Hizmetleri AŞ
- MNT Sağlık Hizmetleri ve Ticaret AŞ
- GAMA Görüntüleme ve Tedavi Hizmetleri AŞ
- Moltek Sağlık Hizmetleri Üretim ve Pazarlama AŞ
Tenders under scrutiny
As part of the investigation, the conduct of the undertakings operating in the relevant market, particularly their behavior in tenders for positron emission tomography (PET), computed tomography (CT), and fluorodeoxyglucose (FDG) held by public hospitals, and the possible effects of these behaviors on competition will be examined.
The Board will assess the activities of the investigated undertakings in the relevant market, with a primary focus on their bidding behavior and competitive conditions in the tenders.
The Competition Board also stressed in its statement that the investigation decision does not mean that the companies under investigation have violated the relevant law or are facing or will face sanctions.
